Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer

Trial Profile

Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 May 2017

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Bladder disorders; Overactive bladder; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms VesiCaP
  • Most Recent Events

    • 17 May 2017 Status changed from recruiting to discontinued.
    • 01 Dec 2016 Status changed from completed to recruiting.
    • 07 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top